Fetal growth disorders detection during first trimester gestation through comprehensive maternal circulating DNA profiling
Human Molecular Genetics · 2025
DOI: 10.1093/hmg/ddaf055 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Molecular Genetics, 2025. Verfasst von Rene Cortese und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecology, Obstetrics and Women's Health, University of Missouri, 1 Hospital Dr. Columbia, MO 65212, United States. Hauptthemen laut MEDLINE: Pregnancy Trimester, First, Cell-Free Nucleic Acids, Fetal Growth Retardation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: University of Missouri.
Abstract (Originalsprache)
Background
Early diagnosis, close follow-up and timely delivery constitute the main elements for appropriate detection and management of Fetal Growth Disorders (FGD). We hypothesized that fetoplacental FGD-associated alterations can be detected in circulating DNA (cirDNA) samples isolated from maternal blood, as early as the first gestational trimester.
Methods
Plasma cirDNA was isolated from samples prospectively collected during first trimester gestation (n = 56). Small, Large and Appropriate for Gestational Age (SGA n = 11, LGA n = 18, and AGA n = 29, respectively) status was determined at birth according to weight and gestational age. cirDNA amount, fragmentation, mitochondrial/nuclear ratio and cirDNA methylation profiles were quantified using qPCR-based assays. Machine learning approaches were applied to build a molecular signature for prediction of LGA and SGA. Prediction accuracy was assessed by Receiver-Operating Curve (ROC) analysis, and Positive and Negative Predictive values (PPV and NPV, respectively) were calculated.
Results
Total concentration of plasma cirDNA, cirDNA fragmentation and ratio of mitochondrial/nuclear cirDNA were increased in SGA and LGA compared to AGA pregnancies. Out of the 10 selected loci, we detected 5 genes (HSD2, RASSF1, CYP19A1, IL10, and LEP) showing significant differential methylation differences (p < 0.05) across the SGA, AGA and LGA samples at first trimester. cirDNA marker signature discriminated between FGD and AGA pregnancies with high accuracy (AUC > 0.95), achieving 88.8% PPV and 85.7% NPV.
Conclusions
Maternal blood cirDNA profiles accurately detects early gestation FGD. The proposed novel marker panel hold great potential for implementation of low invasive approaches for reliable prediction of FGDs, enabling a disruptive path toward precision medicine in FGD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Gynecology, Obstetrics and Women's Health, University of Missouri, 1 Hospital Dr. Columbia, MO 65212, United States.
- Department of Pediatrics, School of Medicine, University of Missouri, 1 Hospital Dr. Columbia, MO 65212, United States.
- Institute for Data Science and Informatics, University of Missouri, Columbia, 22 Heinkel Building, MO 65211 United States.
- Saint Luke's Hospital Maternal Fetal Medicine Specialists, Kansas City, MO, 64111, United States.
Förderung
- University of Missouri
Zitieren
APA
Cortese, R., Cataldo, K., Hummel, J., Smith, G., Ortega, M., Richey, M., Winn, H., Gozal, D., & Goodman, J. R. (2025). Fetal growth disorders detection during first trimester gestation through comprehensive maternal circulating DNA profiling. Human Molecular Genetics. https://doi.org/10.1093/hmg/ddaf055
Vancouver
Cortese R, Cataldo K, Hummel J, Smith G, Ortega M, Richey M, et al. Fetal growth disorders detection during first trimester gestation through comprehensive maternal circulating DNA profiling. Human Molecular Genetics. 2025. doi:10.1093/hmg/ddaf055
BibTeX
@article{Cortese2025,
author = {Cortese, Rene and Cataldo, Kylie and Hummel, Justin and Smith, Gracie and Ortega, Madison and Richey, Madison and Winn, Hung and Gozal, David and Goodman, Jean Ricci},
title = {Fetal growth disorders detection during first trimester gestation through comprehensive maternal circulating DNA profiling},
journal = {Human Molecular Genetics},
year = {2025},
doi = {10.1093/hmg/ddaf055}
}
EUVIMED